COMPANY

Pixyl
Healthcare technology company based in La Tronche, France (Grenoble region)
Founded 2015La Tronche, France (Grenoble region)
Product: Pixyl.Neuro.BV Company: Pixyl
diagnostics, 2025
Background
Accurate assessment of brain atrophy is essential in the diagnosis and monitoring of brain aging and neurodegenerative disorders. Radiological methods range from narrative reporting to semi-quantitative visual rating scales (VRSs) and fully automated volumetric software. However, their integration and consistency in clinical practice remain limited.
Methods
In this retrospective study, brain MRI images of 43 patients were evaluated. Brain atrophy was assessed by extrapolating findings from narrative radiology reports, three validated VRSs (MTA, Koedam, Pasquier), and Pixyl.Neuro.BV, a commercially available volumetric software platform. Agreement between methods was assessed using intraclass correlation coefficients (ICCs), Cohen's kappa, Spearman's correlation, and McNemar tests.
Results
Moderate correlation was found between narrative reports and VRSs (ρ = 0.55-0.69), but categorical agreement was limited (kappa = 0.21-0.30). Visual scales underestimated atrophy relative to software (mean scores: VRSs = 0.196; software = 0.279), while reports tended to overestimate. Agreement between VRSs and software was poor (kappa = 0.14-0.33), though MTA showed a significant correlation with hippocampal volume. Agreement between reports and software was lowest for global atrophy.
Conclusions
Narrative reports, while common in practice, show low consistency with structured scales and quantitative software, especially in subtle cases. VRSs improve standardization but remain subjective and less sensitive. Integrating structured scales and volumetric tools into clinical workflows may enhance diagnostic accuracy and consistency in dementia imaging.